Argatroban for therapeutic anticoagulation for heparin resistance associated with Covid-19 infection
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:51 |
|---|---|
| Enthalten in: |
Journal of thrombosis and thrombolysis - 51(2021), 1 vom: 15. Jan., Seite 243-245 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
McGlynn, Fergal [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
9005-49-6 |
|---|
| Anmerkungen: |
Date Completed 02.02.2021 Date Revised 18.02.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s11239-020-02251-z |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM314039546 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM314039546 | ||
| 003 | DE-627 | ||
| 005 | 20231225151854.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s11239-020-02251-z |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1046.xml |
| 035 | |a (DE-627)NLM314039546 | ||
| 035 | |a (NLM)32830309 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a McGlynn, Fergal |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Argatroban for therapeutic anticoagulation for heparin resistance associated with Covid-19 infection |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 02.02.2021 | ||
| 500 | |a Date Revised 18.02.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a Letter | |
| 650 | 7 | |a Anticoagulants |2 NLM | |
| 650 | 7 | |a Fibrin Fibrinogen Degradation Products |2 NLM | |
| 650 | 7 | |a Pipecolic Acids |2 NLM | |
| 650 | 7 | |a Sulfonamides |2 NLM | |
| 650 | 7 | |a fibrin fragment D |2 NLM | |
| 650 | 7 | |a Heparin |2 NLM | |
| 650 | 7 | |a 9005-49-6 |2 NLM | |
| 650 | 7 | |a Arginine |2 NLM | |
| 650 | 7 | |a 94ZLA3W45F |2 NLM | |
| 650 | 7 | |a argatroban |2 NLM | |
| 650 | 7 | |a IY90U61Z3S |2 NLM | |
| 700 | 1 | |a McGrath, Jennifer |e verfasserin |4 aut | |
| 700 | 1 | |a Varghese, Chithra |e verfasserin |4 aut | |
| 700 | 1 | |a Ryan, Barbara |e verfasserin |4 aut | |
| 700 | 1 | |a McHugh, Johnny |e verfasserin |4 aut | |
| 700 | 1 | |a Fahy, Arabella |e verfasserin |4 aut | |
| 700 | 1 | |a Enright, Helen |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of thrombosis and thrombolysis |d 1994 |g 51(2021), 1 vom: 15. Jan., Seite 243-245 |w (DE-627)NLM094439990 |x 1573-742X |7 nnns |
| 773 | 1 | 8 | |g volume:51 |g year:2021 |g number:1 |g day:15 |g month:01 |g pages:243-245 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s11239-020-02251-z |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 51 |j 2021 |e 1 |b 15 |c 01 |h 243-245 | ||